Vascular toxicities of cancer therapies: The old and the new - An evolving avenue

Joerg Herrmann, Eric H. Yang, Cezar A. Iliescu, Mehmet Cilingiroglu, Konstantinos Charitakis, Abdul Hakeem, Konstantinos Toutouzas, Massoud A. Leesar, Cindy L. Grines, Konstantinos Marmagkiolis

Research output: Contribution to journalReview article

81 Citations (Scopus)

Abstract

Since the late 1990s, there has been a steady decline in cancer-related mortality, in part related to the introduction of so-called targeted therapies. Intended to interfere with a specific molecular pathway, these therapies have, paradoxically, led to a number of effects off their intended cancer tissue or molecular targets. The latest examples are tyrosine kinase inhibitors targeting the Philadelphia Chromosome mutation product, which have been associated with progressive atherosclerosis and acute vascular events. In addition, agents designed to interfere with the vascular growth factor signaling pathway have vascular side effects ranging from hypertension to arterial events and cardiomyocyte toxicity. Interestingly, the risk of cardiotoxicity with drugs such as trastuzumab is predicted by preexisting cardiovascular risk factors and disease, posing the question of a vascular component to the pathophysiology. The effect on the coronary circulation has been the leading explanation for the cardiotoxicity of 5-fluorouracil and may be the underlying the mechanism of presentation of apical ballooning syndrome with various chemotherapeutic agents. Classical chemotherapeutic agents such as cisplatin, often used in combination with bleomycin and vinca alkaloids, can lead to vascular events including acute coronary thrombosis and may be associated with an increased long-term cardiovascular risk. This review is intended to provide an update on the evolving spectrum of vascular toxicities with cancer therapeutics, particularly as they pertain to clinical practice, and to the conceptualization of cardiovascular diseases, as well. Vascular toxicity with cancer therapy: the old and the new, an evolving avenue.

Original languageEnglish (US)
Pages (from-to)1272-1289
Number of pages18
JournalCirculation
Volume133
Issue number13
DOIs
StatePublished - Mar 29 2016

Fingerprint

Blood Vessels
Neoplasms
Therapeutics
Vinca Alkaloids
Takotsubo Cardiomyopathy
Coronary Thrombosis
Philadelphia Chromosome
Coronary Circulation
Bleomycin
Cardiac Myocytes
Fluorouracil
Protein-Tyrosine Kinases
Cisplatin
Atherosclerosis
Intercellular Signaling Peptides and Proteins
Cardiovascular Diseases
Hypertension
Mutation
Mortality
Pharmaceutical Preparations

Keywords

  • angina pectoris
  • chemotherapy
  • complications, cardiovascular
  • coronary vasospasm
  • drug therapy
  • endothelial cells

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Herrmann, J., Yang, E. H., Iliescu, C. A., Cilingiroglu, M., Charitakis, K., Hakeem, A., ... Marmagkiolis, K. (2016). Vascular toxicities of cancer therapies: The old and the new - An evolving avenue. Circulation, 133(13), 1272-1289. https://doi.org/10.1161/CIRCULATIONAHA.115.018347

Vascular toxicities of cancer therapies : The old and the new - An evolving avenue. / Herrmann, Joerg; Yang, Eric H.; Iliescu, Cezar A.; Cilingiroglu, Mehmet; Charitakis, Konstantinos; Hakeem, Abdul; Toutouzas, Konstantinos; Leesar, Massoud A.; Grines, Cindy L.; Marmagkiolis, Konstantinos.

In: Circulation, Vol. 133, No. 13, 29.03.2016, p. 1272-1289.

Research output: Contribution to journalReview article

Herrmann, J, Yang, EH, Iliescu, CA, Cilingiroglu, M, Charitakis, K, Hakeem, A, Toutouzas, K, Leesar, MA, Grines, CL & Marmagkiolis, K 2016, 'Vascular toxicities of cancer therapies: The old and the new - An evolving avenue', Circulation, vol. 133, no. 13, pp. 1272-1289. https://doi.org/10.1161/CIRCULATIONAHA.115.018347
Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A et al. Vascular toxicities of cancer therapies: The old and the new - An evolving avenue. Circulation. 2016 Mar 29;133(13):1272-1289. https://doi.org/10.1161/CIRCULATIONAHA.115.018347
Herrmann, Joerg ; Yang, Eric H. ; Iliescu, Cezar A. ; Cilingiroglu, Mehmet ; Charitakis, Konstantinos ; Hakeem, Abdul ; Toutouzas, Konstantinos ; Leesar, Massoud A. ; Grines, Cindy L. ; Marmagkiolis, Konstantinos. / Vascular toxicities of cancer therapies : The old and the new - An evolving avenue. In: Circulation. 2016 ; Vol. 133, No. 13. pp. 1272-1289.
@article{17c1590d4b104ad0a3a2b75be7399ea8,
title = "Vascular toxicities of cancer therapies: The old and the new - An evolving avenue",
abstract = "Since the late 1990s, there has been a steady decline in cancer-related mortality, in part related to the introduction of so-called targeted therapies. Intended to interfere with a specific molecular pathway, these therapies have, paradoxically, led to a number of effects off their intended cancer tissue or molecular targets. The latest examples are tyrosine kinase inhibitors targeting the Philadelphia Chromosome mutation product, which have been associated with progressive atherosclerosis and acute vascular events. In addition, agents designed to interfere with the vascular growth factor signaling pathway have vascular side effects ranging from hypertension to arterial events and cardiomyocyte toxicity. Interestingly, the risk of cardiotoxicity with drugs such as trastuzumab is predicted by preexisting cardiovascular risk factors and disease, posing the question of a vascular component to the pathophysiology. The effect on the coronary circulation has been the leading explanation for the cardiotoxicity of 5-fluorouracil and may be the underlying the mechanism of presentation of apical ballooning syndrome with various chemotherapeutic agents. Classical chemotherapeutic agents such as cisplatin, often used in combination with bleomycin and vinca alkaloids, can lead to vascular events including acute coronary thrombosis and may be associated with an increased long-term cardiovascular risk. This review is intended to provide an update on the evolving spectrum of vascular toxicities with cancer therapeutics, particularly as they pertain to clinical practice, and to the conceptualization of cardiovascular diseases, as well. Vascular toxicity with cancer therapy: the old and the new, an evolving avenue.",
keywords = "angina pectoris, chemotherapy, complications, cardiovascular, coronary vasospasm, drug therapy, endothelial cells",
author = "Joerg Herrmann and Yang, {Eric H.} and Iliescu, {Cezar A.} and Mehmet Cilingiroglu and Konstantinos Charitakis and Abdul Hakeem and Konstantinos Toutouzas and Leesar, {Massoud A.} and Grines, {Cindy L.} and Konstantinos Marmagkiolis",
year = "2016",
month = "3",
day = "29",
doi = "10.1161/CIRCULATIONAHA.115.018347",
language = "English (US)",
volume = "133",
pages = "1272--1289",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "13",

}

TY - JOUR

T1 - Vascular toxicities of cancer therapies

T2 - The old and the new - An evolving avenue

AU - Herrmann, Joerg

AU - Yang, Eric H.

AU - Iliescu, Cezar A.

AU - Cilingiroglu, Mehmet

AU - Charitakis, Konstantinos

AU - Hakeem, Abdul

AU - Toutouzas, Konstantinos

AU - Leesar, Massoud A.

AU - Grines, Cindy L.

AU - Marmagkiolis, Konstantinos

PY - 2016/3/29

Y1 - 2016/3/29

N2 - Since the late 1990s, there has been a steady decline in cancer-related mortality, in part related to the introduction of so-called targeted therapies. Intended to interfere with a specific molecular pathway, these therapies have, paradoxically, led to a number of effects off their intended cancer tissue or molecular targets. The latest examples are tyrosine kinase inhibitors targeting the Philadelphia Chromosome mutation product, which have been associated with progressive atherosclerosis and acute vascular events. In addition, agents designed to interfere with the vascular growth factor signaling pathway have vascular side effects ranging from hypertension to arterial events and cardiomyocyte toxicity. Interestingly, the risk of cardiotoxicity with drugs such as trastuzumab is predicted by preexisting cardiovascular risk factors and disease, posing the question of a vascular component to the pathophysiology. The effect on the coronary circulation has been the leading explanation for the cardiotoxicity of 5-fluorouracil and may be the underlying the mechanism of presentation of apical ballooning syndrome with various chemotherapeutic agents. Classical chemotherapeutic agents such as cisplatin, often used in combination with bleomycin and vinca alkaloids, can lead to vascular events including acute coronary thrombosis and may be associated with an increased long-term cardiovascular risk. This review is intended to provide an update on the evolving spectrum of vascular toxicities with cancer therapeutics, particularly as they pertain to clinical practice, and to the conceptualization of cardiovascular diseases, as well. Vascular toxicity with cancer therapy: the old and the new, an evolving avenue.

AB - Since the late 1990s, there has been a steady decline in cancer-related mortality, in part related to the introduction of so-called targeted therapies. Intended to interfere with a specific molecular pathway, these therapies have, paradoxically, led to a number of effects off their intended cancer tissue or molecular targets. The latest examples are tyrosine kinase inhibitors targeting the Philadelphia Chromosome mutation product, which have been associated with progressive atherosclerosis and acute vascular events. In addition, agents designed to interfere with the vascular growth factor signaling pathway have vascular side effects ranging from hypertension to arterial events and cardiomyocyte toxicity. Interestingly, the risk of cardiotoxicity with drugs such as trastuzumab is predicted by preexisting cardiovascular risk factors and disease, posing the question of a vascular component to the pathophysiology. The effect on the coronary circulation has been the leading explanation for the cardiotoxicity of 5-fluorouracil and may be the underlying the mechanism of presentation of apical ballooning syndrome with various chemotherapeutic agents. Classical chemotherapeutic agents such as cisplatin, often used in combination with bleomycin and vinca alkaloids, can lead to vascular events including acute coronary thrombosis and may be associated with an increased long-term cardiovascular risk. This review is intended to provide an update on the evolving spectrum of vascular toxicities with cancer therapeutics, particularly as they pertain to clinical practice, and to the conceptualization of cardiovascular diseases, as well. Vascular toxicity with cancer therapy: the old and the new, an evolving avenue.

KW - angina pectoris

KW - chemotherapy

KW - complications, cardiovascular

KW - coronary vasospasm

KW - drug therapy

KW - endothelial cells

UR - http://www.scopus.com/inward/record.url?scp=84962529928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962529928&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.115.018347

DO - 10.1161/CIRCULATIONAHA.115.018347

M3 - Review article

C2 - 27022039

AN - SCOPUS:84962529928

VL - 133

SP - 1272

EP - 1289

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 13

ER -